ArticleFrontiers in pharmacology2026
Renal safety of postoperative short-term use of flurbiprofen axetil in well-controlled hypertensive patients: a prospective multicenter cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, postoperative nonsteroidal anti-inflammatory drugs-associated kidney damage in hypertensive patients remains undetermined. This study aimed to examine renal safety of short-term post-surgery use of flurbiprofen axetil (FA) in well-controlled hypertensive patients. Methods: Data were collected from January 2020 to March 2021 at four major hospitals on patients who had undergone total knee replacement surgery (TKA). Patients were divided into well-controlled hypertensive and normotensive groups, and received short-term intravenous FA postoperatively. The primary outcomes were trajectory changes of postoperative renal injury biomarkers. Second outcomes included acute kidney injury (AKI), pain intensity and other complications. Results: A total of 120 patients were enrolled. Post-surgery FA significantly reduced pain in both groups. The results of repeated measures analysis of variance (ANOVA) demonstrated that the main effects of group, time and the group-by-time interaction on blood urea nitrogen (BUN), serum creatine (SCr) and Cystatin C (Cys C) levels were not statistically significant on postoperative day 2 and 5 (POD2 and POD5) (all P > 0.05). Urine N-acetyl-beta-glucosaminidase (NAG) levels were significantly higher on POD2 and POD5 in both groups [preoperative: (6.66 ± 4.87) U/L, POD2: (10.07 ± 6.88) U/L, POD5: (10.25 ± 7.68) U/L in normotensive group; preoperative: (7.39 ± 4.07) U/L, POD2: (12.34 ± 7.1) U/L, POD5: (15.57 ± 12.34) U/L in well-controlled hypertensive group; all P < 0.001] compared with baseline. However, only the well-controlled hypertensive group showed a continued increase in NAG levels on POD5 (P = 0.039). AKI occurred in 7.0% (4/57) and 3.2% (2/63) of well-controlled hypertensive and normotensive patients (P = 0.335), and all the AKI patients were at stage 1. After adjusting for confounding factors, hypertension had no impact on AKI (OR = 0.733, 95%CI: 0.074-7.222, P = 0.790). No significant differences in other complications were observed between the groups. Conclusion: The current FA regimen after surgery is effective, and it does not increase AKI incidence in well-controlled hypertensive TKA patients, thought posing a risk of tubular damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.